Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
3.
J Invest Dermatol ; 135(7): 1781-1789, 2015 Jul.
Article in English | MEDLINE | ID: mdl-25668238

ABSTRACT

A major deleterious side effect of glucocorticoids is skin atrophy. Glucocorticoids activate the glucocorticoid and the mineralocorticoid (MR) receptor, both present in the epidermis. We hypothesized that glucocorticoid-induced epidermal atrophy may be related to inappropriate occupancy of MR by glucocorticoids. We evaluated whether epidermal atrophy induced by the topical glucocorticoid clobetasol could be limited by coadministration of MR antagonist. In cultured human skin explants, the epidermal atrophy induced by clobetasol was significantly limited by MR antagonism (canrenoate and eplerenone). Blockade of the epithelial sodium channel ENaC by phenamil was also efficient, identifying a role of MR-ENaC cascade in keratinocytes, acting through restoration of clobetasol-induced impairment of keratinocyte proliferation. In the SPIREPI randomized double-blind controlled trial, gels containing clobetasol, the MR antagonist spironolactone, both agents, or placebo were applied on four zones of the forearms of 23 healthy volunteers for 28 days. Primary outcome was histological thickness of the epidermis with clobetasol alone or clobetasol+spironolactone. Spironolactone alone did not affect the epidermal thickness but coapplication of clobetasol and spironolactone significantly limited clobetasol-induced atrophy and was well tolerated. Altogether, these findings identify MR as a factor regulating epidermal homeostasis and suggest that topical MR blockade could limit glucocorticoid-induced epidermal atrophy.


Subject(s)
Clobetasol/administration & dosage , Epidermis/pathology , Glucocorticoids/adverse effects , Mineralocorticoid Receptor Antagonists/administration & dosage , Receptors, Mineralocorticoid/drug effects , Spironolactone/administration & dosage , Administration, Topical , Adult , Atrophy/chemically induced , Atrophy/drug therapy , Atrophy/pathology , Biopsy, Needle , Dermoscopy/methods , Double-Blind Method , Epidermis/drug effects , Female , Glucocorticoids/administration & dosage , Healthy Volunteers , Humans , Immunohistochemistry , Male , Middle Aged , Reference Values , Risk Assessment , Statistics, Nonparametric , Treatment Outcome , Young Adult
4.
Eur J Dermatol ; 20(4): 461-4, 2010.
Article in English | MEDLINE | ID: mdl-20507840

ABSTRACT

Fixed drug eruption (FDE) is one of the most typical cutaneous drug adverse reactions. This localized drug-induced reaction is characterized by its relapse at the same sites. Few large series of FDE are reported. The aim of this study was to retrospectively collect and analyse well informed cases observed in a hospital setting. This study involved 17 academic clinical centers. A French nation-wide retrospective multicentric study was carried out on a 3-year-period from 2005 to 2007 by collecting data in seventeen departments of dermatology in France. Diagnosis of FDE was based essentially on clinical findings, at times confirmed by pathological data and patch-testing. Records were reviewed for demographics, causative drugs, localization, severity, and patch-tests, when available. Fifty nine cases were analysed. Patients were 59-years-old on average, with a female predilection. The most common drug was paracetamol, followed by the non-steroidal anti inflammatory drugs. The time between drug intake and skin symptoms was, on average, two days. Beside these classical characteristics, some original findings were found including, a frequent non pigmentation course and a sex-dependent pattern of distribution. Women often had lesions on the hands and feet, and men on the genitalia. Given the fact that skin pigmentation is an inconstant feature of FDE, its French name (erythème pigmenté fixe) should be reconsidered. The sex-dependent distribution could help our understanding of the pathophysiology of fixed drug eruption.


Subject(s)
Adverse Drug Reaction Reporting Systems , Drug Eruptions/epidemiology , Acetaminophen/adverse effects , Adolescent , Adult , Aged , Aged, 80 and over , Analgesics/adverse effects , Analysis of Variance , Anti-Bacterial Agents/adverse effects , Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Child , Drug Eruptions/diagnosis , Drug Eruptions/etiology , Female , France/epidemiology , Humans , Male , Middle Aged , Patch Tests , Retrospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...